This study analyzed tumor doubling times (TDT) in four cases of primary cutaneous melanoma with delayed diagnoses and their corresponding metastases. The median/mean TDT for primary melanomas was 94/144 days (range: 50–377 days), while metastatic melanomas exhibited a significantly faster TDT of 33/64 days (range: 8–212 days) (P = 0.01).
This 2012 review examines the rapid tumor doubling time characteristic of small cell lung cancer (SCLC), with reported rates ranging from 25 to 217 days. The rapid proliferation contributes to aggressive clinical behavior and often presents with symptoms that mimic benign pulmonary conditions, such as infections, which can delay diagnosis.
This 1995 foundational review aggregates clinical and laboratory data to evaluate growth kinetics of various human solid tumors, including breast, lung, colorectal cancers, melanomas, and skeletal sarcomas. It analyzes tumor growth using both gross measurements (e.g., imaging, palpation) and cytokinetic parameters such as tritiated thymidine and bromodeoxyuridine labeling, S-phase fractions,
This 2019 study presents a novel statistical methodology to estimate tumor doubling times (TDTs) from published progression-free survival (PFS) plots, facilitating better understanding of tumor growth dynamics in solid malignancies. Researchers extracted PFS curves from clinical trials encompassing twelve cancer types, including pancreatic, melanoma, hepatocellular carcinoma, renal cell carcinoma, triple-negative
